Patents Examined by Lisa J. Hobbs
  • Patent number: 8637007
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: January 28, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Marie-Christine Canavaggio
  • Patent number: 8637640
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: January 28, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Patent number: 8617839
    Abstract: The present invention is a method of extracting infectious pathogens from a volume of blood including the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The fibrin lysis reagent is preferably composed of plasminogen and streptokinase frozen in coincident relation until the fibrin lysis reagent is needed whereby streptokinase enzymatically reacts with plasminogen to form plasmin upon thawing. The plasminogen is suspended in an aqueous salt solution prior to freezing including NaCl and Na3PO4.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: December 31, 2013
    Assignee: University of South Florida
    Inventor: Matt Ewert
  • Patent number: 8617615
    Abstract: The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: December 31, 2013
    Inventor: Jean-Louis Dasseux
  • Patent number: 8609126
    Abstract: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: December 17, 2013
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventors: Eugene Michal, Shubhayu Basu, Hai-Chien Kuo
  • Patent number: 8586294
    Abstract: Methods and compositions are provided for detecting molecular translocations, particularly protein translocations within and between subcellular copartments, using at least two components that exhibit a localization-dependent difference in complementation activity. In particular, alpha-complementing ?-galactosidase fragments are provided. These ?-galactosidase reporter fragments display significantly enhanced enzymatic activity when one fragment is localized in a membrane. Methods for carrying out no-wash ELISA assays based on the reporter component system are also provided.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: November 19, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Thomas S. Wehrman
  • Patent number: 8580532
    Abstract: To provide a method for stabilizing unstable ?-thrombin in a thrombin-containing solution, a solution containing stabilized ?-thrombin, and a liquid fibrinogen assay reagent containing the solution. The method for stabilizing ?-thrombin in a thrombin-containing solution, which includes adjusting the percentage of ?-thrombin to 70% or more with respect to the amount of total thrombin in the thrombin-containing solution.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: November 12, 2013
    Assignee: Sekisui Medical Co., Ltd.
    Inventors: Remi Ikeda, Chizuru Morikawa, Hirokazu Yago
  • Patent number: 8580550
    Abstract: There is provided a lipase powder which is a granulated material comprising a lipase and at least one member selected from the group consisting of fatty acids having 8 to 12 carbon atoms, alcohol esters thereof, and a mixture thereof. This lipase powder has an increased lipase activity.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: November 12, 2013
    Assignee: The Nisshin OilliO Group, Ltd.
    Inventors: Tomomi Suganuma, Tadashiro Hirose, Junko Suzuki, Shin Arimoto, Hideaki Maki, Satoshi Negishi
  • Patent number: 8568970
    Abstract: Compositions containing bacteriophages and methods of using bacteriophages in microorganism detection assays and microbial growth and plating media are disclosed. The lytic ability of these phages to control the growth of non-target populations provides superior sensitivity and specificity to detection assays and reduces false negative and false positive results. The removal of contaminating bacteria reduces the microbial competition for nutrients in the growth media thereby increasing the efficiency and productivity of the culture. The phage treatment of the sample increases the proportion of target microorganisms in the sample over contaminating bacteria thereby requiring less time for enrichment to obtain a significant signal improving overall signal to noise ratio in assays and providing for higher yield of end product in microbiological production systems.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: October 29, 2013
    Assignee: Romer Labs Technology, Inc.
    Inventors: James W. Stave, George B. Teany, III
  • Patent number: 8562980
    Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
    Type: Grant
    Filed: February 2, 2011
    Date of Patent: October 22, 2013
    Assignee: Aptalis Pharma Limited
    Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
  • Patent number: 8562978
    Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: October 22, 2013
    Assignee: Aptalis Pharma Limited
    Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
  • Patent number: 8562981
    Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
    Type: Grant
    Filed: February 2, 2011
    Date of Patent: October 22, 2013
    Assignee: Aptalis Pharma Limited
    Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
  • Patent number: 8562979
    Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
    Type: Grant
    Filed: February 2, 2011
    Date of Patent: October 22, 2013
    Assignee: Aptalis Pharma Limited
    Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
  • Patent number: 8535926
    Abstract: Two novel cellulases and nucleotide sequences encoding the same are disclosed. Also disclosed are compositions and methods for using the same for hydrolyzing cellulosic waste materials.
    Type: Grant
    Filed: March 13, 2011
    Date of Patent: September 17, 2013
    Assignee: Academia Sinica
    Inventors: Yu-Chan Chao, Chia-Jung Chang
  • Patent number: 8535738
    Abstract: A method for formulating products to normalize skin or treat irritated or inflamed skin, a method for normalizing skin or treating irritated or inflamed skin for improvement, and compositions therefor.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: September 17, 2013
    Assignee: ELC Management, LLC
    Inventors: Donald F. Collins, Daniel H. Maes, Neelam Muizzuddin
  • Patent number: 8501433
    Abstract: The present invention relates to a non-toxic dipolar solvent for chromogenic substrate for detecting presence of lacZ gene and/or gene activity, which comprises a stabilizing amount of a solubilizing agent. The present invention also relates to a method for inducing lac operon in screening assay, comprising the step of contacting an agar plate with at least one essential oil in a concentration sufficient to induce the lac operon. The present invention further relates to a method for detecting the presence of bacteria, comprising the step of contacting an agar plate with at least one essential oil in a concentration sufficient to induce detection of the bacteria.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: August 6, 2013
    Assignee: Pierce Biotechnology, Inc.
    Inventors: Pierre Sévigny, Martina Bielefeld-Sévigny
  • Patent number: 8497106
    Abstract: A method of immobilising a biological molecule on a substrate comprises: (i) covalently attaching a substantially three-dimensional polysilane polymer to a substrate; and (ii) attaching a biological molecule onto and/or within the polymer. The method may additionally comprise the steps of coating the substrate (or the chemically protective layer) with a layer of radiation sensitive material, exposing the substrate to a source of radiation, and incubating the substrate in the presence of a first species of biological molecule.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: July 30, 2013
    Assignee: The University of Newcastle
    Inventor: Guillaume Suarez
  • Patent number: 8389441
    Abstract: The present invention is directed to methods for delaying a plant development process comprising exposing a plant or plant part to one or more bacteria or enzymes. In specific embodiments, the one or more bacteria are selected from the group consisting of Rhodococcus spp., Pseudomonas chloroaphis, Brevibacterium ketoglutamicum, and a mixture comprising any combination of these bacteria. Apparatuses for delaying a plant development process comprising a catalyst that comprises one or more of the above bacteria.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: March 5, 2013
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: George E. Pierce, Sangeeta Ganguly, Gene K. Drago
  • Patent number: 8372599
    Abstract: This invention relates to a culture medium, a kit containing the culture medium and to a method for detection of a parasite such as Dientamoeba fragilis and/or another parasite. The culture medium of the invention is bi-phasic and includes a solid phase containing an egg slope or agar slope; and a liquid phase including a serum and a peptone.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: February 12, 2013
    Inventor: Thomas Julius Borody
  • Patent number: 8361742
    Abstract: A method and system for rapidly detecting Candida on the skin of a host, such as an infant with diaper rash, is provided. The method includes contacting a dermal sample with a colorant that exhibits a certain spectral response (e.g., color change) in the presence of Candida. For example, the colorant may change from a first color to a second color, from colorless to a color, or from a color to colorless. The colorant is typically capable of differentiating between Candida (e.g., Candida albicans) and other microorganisms commonly associated with diaper rash, such as S. aureus and E. coli. Thus, when a dermal sample is placed into contact with the colorant, the color change may simply be observed to determine whether the infection is caused by Candida. If the color change occurs to a certain extent (e.g., from yellow to bright red), it may be determined that the test sample contains Candida. Likewise, if a color change occurs to a lesser extent (e.g.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: January 29, 2013
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Stephanie M. Martin, Andrew M. Long, III, John Gavin MacDonald, Jason Lye